Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ESTABLISHMENT LABS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ESTABLISHMENT LABS HOLDINGS's regulatory disclosures and financial reporting.
Establishment Labs Holdings Inc. has appointed Taylor Harris to its Board of Directors, effective immediately, to serve until the 2027 annual meeting of shareholders. He will also sit on the Audit Committee and the Nominating and Corporate Governance Committee.
Harris will receive the company’s standard non-employee director cash and equity compensation, including an updated initial equity grant of $170,000 for new directors and a $170,000 annual equity grant. The Board determined that all members of the Audit, Compensation, and Nominating and Corporate Governance Committees meet Nasdaq independence standards.
The accompanying press release highlights Harris’s 25+ years of experience in healthcare and medical technology, including leadership roles at Cutera, MyoKardia, Zeltiq Aesthetics, and Thoratec, and his involvement in major strategic transactions such as MyoKardia’s $13.1 billion acquisition by Bristol Myers Squibb.
Issuer filed a Form 144 reporting a proposed sale of 24,198 common shares via a stock option exercise on 06/15/2026, with cash as the payment method. The filing also lists multiple prior open-market dispositions by Sariel Group Ltd dated between 03/23/2026 and 05/06/2026, including sales such as 37,500 shares for $2,446,050 on 04/14/2026. The notice documents the method and per‑trade amounts for these recent dispositions.
JW Asset Management–affiliated funds sold Establishment Labs shares and fell below a 10% ownership threshold. JW Partners and JW Opportunities Fund sold a total of 90,533 common shares in open-market trades on May 26–28, 2026 at prices around $72–$74 per share. After these sales, the reporting group indirectly held 2,890,582 shares. The Form 4 states this transaction caused the reporting persons to cease being beneficial owners of more than 10% of Establishment Labs’ common stock, and it is described as their final Form 4 for this issuer. The advisor and related entities disclaim beneficial ownership beyond their indirect pecuniary interests.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Bryan Slotkin received an award of 2,354 common share stock units as compensation. The units were granted at a stated price of $0.00 per share under the company’s 2018 Equity Incentive Plan.
The shares subject to this award vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, as long as Slotkin continues as a service provider through that date. After this grant, he directly holds 32,610 common shares.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter received an equity award of 2,354 common share units on May 22, 2026, at no cash cost to him. This grant was made under the company’s 2018 Equity Incentive Plan as part of his director compensation.
The stock units vest in full on the earlier of May 22, 2027 or the day before the company’s next annual stockholder meeting, as long as he continues as a service provider through that date. After this award, Schutter directly holds 177,736 common shares.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. reported that director Ann Custin received an award of 2,354 common share stock units as equity compensation. The award was granted at no cash cost and increases her direct holdings to 24,086 common shares. The units vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, provided she continues as a service provider through that date.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received an award of 2,354 common share units at no cost under the company’s 2018 Equity Incentive Plan. The units vest in full on the earlier of May 22, 2027 or the day before the next annual meeting, if he continues as a service provider.
Following this grant, he holds 1,079,669 common shares directly and 19,090 common shares indirectly through his spouse.
Gillin Leslie reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Leslie Gillin received an award of 2,354 common share stock units as compensation. The award was granted at no cash cost to her and is tied to continued board service. These units vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, provided she remains a service provider through that date. Following this grant, she holds 18,398 common shares directly.
ESTABLISHMENT LABS HOLDINGS INC. saw affiliated investment funds managed by JW Asset Management report open-market sales of its Common Shares. On May 20, 2026, a total of 3,580 shares were sold at $70.56 per share, and on May 21, 2026, 16,999 shares were sold at $71.40 per share. Footnotes state these transactions reflect 15,350 shares sold by JW Partners, LP and 5,229 shares sold by JW Opportunities Fund, LLC. After these trades, the reporting group collectively reports holding 2,981,115 Common Shares indirectly. The Advisor, the General Partner and Jason G. Wild each disclaim beneficial ownership except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings Inc. held its Annual Meeting of Shareholders on May 22, 2026. Shareholders elected six directors to serve until the 2027 annual meeting, including Filippo “Peter” Caldini, who received 20,009,113 votes for and 21,173 against, and Edward Schutter, who received 20,001,165 votes for and 29,105 against.
Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers with 19,999,556 votes for and 30,543 against, with 3,063,262 broker non-votes. In addition, they ratified the appointment of CBIZ, CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 22,686,230 votes for and 405,748 against.